Optimization of initial tacrolimus dose using pharmacogenetic testing.

@article{Thervet2010OptimizationOI,
  title={Optimization of initial tacrolimus dose using pharmacogenetic testing.},
  author={Eric Thervet and Marie Anne Loriot and Suzanne Barbier and Mathias Buchler and Maxence Ficheux and Gabriel Choukroun and Olivier Toupance and Guy Touchard and Corinne Alberti and Patrick Le Pogamp and Bruno Moulin and Yannick Le Meur and A E Heng and J F Subra and Philippe H. Beaune and C. Legendre},
  journal={Clinical pharmacology and therapeutics},
  year={2010},
  volume={87 6},
  pages={721-6}
}
Retrospective studies have demonstrated that patients who are expressors of cytochrome P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough concentration (C(0)). The aim of this study was to evaluate this effect prospectively by pretransplantation adaptation. We randomly assigned 280 renal transplant recipients to receive tacrolimus either according to CYP3A5 genotype or according to the standard daily regimen. The primary end point was the proportion of patients… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 121 extracted citations

Pharmacogenetics of tacrolimus: ready for clinical translation?

Kidney international supplements • 2011
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…